November 5, 2012 — Medtronic Inc. announced new findings from the Medtronic CoreValve ADVANCE Study for one-year survival and health-related quality of life (HRQoL). The findings were presented at Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2012 in Miami.
Initial one-year results of the ADVANCE Study revealed that patients experienced high survival rates, with one-year survival at 82.1 percent and one-year cardiovascular survival at 88.2 percent.
HRQoL measures for patients in the ADVANCE Study improved significantly at one and six months, compared with their status prior to receiving the Medtronic CoreValve System. The ADVANCE study represents the largest, most rigorously collected evaluation of HRQoL findings published on transcatheter aortic valve implantation (TAVI).
The CoreValve System is currently limited to investigational use in the United States.
April 17, 2024 
